Dishman Carbogen Amcis Ltd Surges to 52-Week High, Outperforms Sector and Sensex
Dishman Carbogen Amcis Ltd, a smallcap pharmaceutical company, has seen a surge in its share price, reaching a 52-week high of Rs. 266 on February 28, 2024. Despite being given a 'Sell' call by MarketsMojo, the stock has outperformed the sector by 3.24% and has shown consecutive gains in the last 2 days. With high volatility and trading above its moving averages, the stock has caught the attention of traders. In the past year, Dishman Carbogen has outperformed the Sensex, showcasing its strong growth and potential in the pharmaceutical industry.
Dishman Carbogen Amcis Ltd, a smallcap pharmaceutical company, has been making headlines in the stock market as its share price touched a 52-week high of Rs. 266 on February 28, 2024. This surge in price has caught the attention of investors and analysts alike.
According to MarketsMOJO, a leading stock market analysis platform, the stock has been given a 'Sell' call. However, the company's performance today has outperformed the sector by 3.24%. The stock has also been on a consecutive gain for the last 2 days, with a rise of 10.33% in this period. The intraday high of Rs. 266 marks a 4.7% increase from the previous day's closing price.
The stock has shown high volatility today, with an intraday volatility of 5.28%, calculated from the weighted average price. This indicates a significant movement in the stock's price, making it an attractive option for traders.
In addition, Dishman Carbogen is currently trading higher than its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages. This suggests a positive trend in the stock's performance.
In the past year, Dishman Carbogen has outperformed the Sensex, with a 122.08% return compared to the Sensex's 23.96% performance. This showcases the company's strong growth and potential in the pharmaceutical industry.
Overall, Dishman Carbogen Amcis Ltd has been making waves in the stock market with its recent surge in share price and positive performance. Investors and analysts will continue to keep a close eye on this smallcap company as it continues to make its mark in the pharma industry.
{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)
{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)
Related Stock Links
- {{stockdata.stock.stock_name.value}} Analysis
- {{stockdata.stock.stock_name.value}} Technicals
- {{stockdata.stock.stock_name.value}} Quality
- {{stockdata.stock.stock_name.value}} Valuation
- {{stockdata.stock.stock_name.value}} Financial Trend
- {{stockdata.stock.stock_name.value}} Return Analysis
- {{stockdata.stock.stock_name.value}} Price Analysis
- {{stockdata.stock.stock_name.value}} Quarterly Result Analysis
- {{stockdata.stock.stock_name.value}} Half-Yearly Result Analysis
- {{stockdata.stock.stock_name.value}} Nine Monthly Result Analysis
- {{stockdata.stock.stock_name.value}} Annual Results
- {{stockdata.stock.stock_name.value}} Balance Sheet
- {{stockdata.stock.stock_name.value}} Profit & Loss
- {{stockdata.stock.stock_name.value}} Cash Flow
- {{stockdata.stock.stock_name.value}} News
- {{stockdata.stock.stock_name.value}} Announcements
- {{stockdata.stock.stock_name.value}} Share Holding
- {{stockdata.stock.stock_name.value}} Peer Comparison
Our weekly and monthly stock recommendations are here
Loading...
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Target Price
{{sm.target_price }}
({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
₹{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News
Most Read
